HI-TECH PHARMACAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Launches an Investigation of Hi-Tech Phar

Updated

HI-TECH PHARMACAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Launches an Investigation of Hi-Tech Pharmacal Co., Inc. (HITK) Over the Proposed Sale of the Company to Akorn, Inc. (AKRX)

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors ofHi-Tech Pharmacal Co., Inc.

NEW YORK--(BUSINESS WIRE)-- Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hi-Tech Pharmacal Co., Inc. ("Hi-Tech" or the "Company") (NasdaqGS: HITK) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Akorn, Inc. (NasdaqGS: AKRX) in a deal valued at $640 million. Under the terms of the proposed transaction, Hi-Tech's stockholders will receive $43.50 in cash for each share of Hi-Tech common stock they own. However, Hi-Tech has reached $44.30 in its 52-week high.


Request more information now by clicking here:www.faruqilaw.com/HITK.There is no cost or obligation to you.

The investigation focuses on whether Hi-Tech's Board of Directors breached their fiduciary duties to the Company's stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of Hi-Tech's shareholders.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.

If you own common stock in Hi-Tech and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/HITK or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.



Faruqi & Faruqi, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Juan E. Monteverde, Esq.
jmonteverde@faruqilaw.com
Toll Free: 877-247-4292
Phone: 212-983-9330

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS:

The article HI-TECH PHARMACAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Launches an Investigation of Hi-Tech Pharmacal Co., Inc. (HITK) Over the Proposed Sale of the Company to Akorn, Inc. (AKRX) originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement